Welcome to this UK AstraZeneca produced and funded website
This website is intended for UK Healthcare Professionals only.
The website contains both promotional and non-promotional content.
If you are a patient or a carer of a patient prescribed an AstraZeneca product, please visit myazmed.co.uk
For any other UK residents please visit astrazeneca.co.uk
This website is intended for UK Healthcare Professionals only. Other UK residents please visit astrazeneca.co.uk
This advancement maintains therapeutic efficacy while significantly reducing the carbon footprint and environmental impact of the inhaler (versus current propellants), aligning with NHS sustainability goals.1-3
AZ aims to transition supply from H2 2025
HFO-1234ze represents a significant advancement in inhaler technology, offering a more sustainable alternative to current propellants such as HFA-134a1,4
a HFA-134a; b HFO-1234ze; c Including prescription collection and delivery; Figure adapted from Hargreaves C, et al. Oral presentation at BTS 2022 (Abstract S60)
By using this low-carbon pMDI, healthcare professionals can help reduce the overall environmental impact of COPD treatment while maintaining the benefits of a metered dose inhaler.1
Propellants play a crucial role in pressurised metered dose inhalers (pMDIs), supporting the delivery of medication to the lungs. Historically, the most common propellants used in inhalers have evolved:
It's important to note that dry powder inhalers (DPIs) do not contain propellants, as they rely on the patient's inspiratory effort to deliver the medication.
The propellant in pMDIs typically makes up more than 99% of the inhaler's contents by weight. In addition to the propellant, pMDIs may contain small amounts of other excipients such as co-solvents or surfactants to help stabilize the formulation, or engineered particles such as AEROSPHERE.10
While propellants are essential for pMDI function, their environmental impact has become a significant concern. HFA-134a, for instance, has a high GWP of 1530.4 This has led to the development of next-generation propellants like HFO-1234ze, which maintain the benefits of pMDIs while dramatically reducing environmental impact.9
Optimising care by implementing evidence-based guidelines can reduce exacerbations and decrease the overall carbon footprint associated with respiratory care12-14
a Data from a retrospective study on annualized GHG emissions associated with types of healthcare resource utilisation by severity and frequency of COPD exacerbation, among people with COPD in England (2014-2019). Figure adapted from Bell J, et al. Poster presented at ATS 2024 (Poster P192).
For UK clinicians, it's important to note that TRIXEO AEROSPHERE with the new HFO-1234ze propellant maintains:
The transition to a next-generation propellant in TRIXEO AEROSPHERE supports the NHS Net Zero ambition, as inhalers contribute 3% to the total NHS carbon footprint3
For more information on prescribing TRIXEO AEROSPHERE and its role
in sustainable COPD management
ARR, absolute rate reduction; BFF, budesonide/formoterol fumarate; CI, confidence interval; COPD, chronic obstructive pulmonary disease; DPI, dry powder inhaler; GFF, glycopyrronium/formoterol fumarate; ICS, inhaled corticosteroid; LABA, long-acting beta2-agonist; LAMA, long-acting muscarinic antagonist; NNT, number needed to treat; pMDI, pressurised metered-dose inhaler; RR, rate ratio.
GB-66935 | May 2025
TRIXEO and AEROSPHERE are registered trademarks of the AstraZeneca group of companies.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to AstraZeneca by visiting https://contactazmedical.astrazeneca.com/ or by calling 0800 783 0033.
This website was created for UK HCPs and has been designed to provide information to educate, empower and enable them in the great work they are doing for patients across a range of therapy areas. This website is intended for doctors, nurses, and pharmacists in the UK. Other UK residents please visit astrazeneca.co.uk.
